IRIS
VIGNA, ERNESTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.969
AS - Asia 2.751
EU - Europa 1.178
SA - Sud America 774
Continente sconosciuto - Info sul continente non disponibili 137
AF - Africa 117
OC - Oceania 6
AN - Antartide 1
Totale 7.933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.750
SG - Singapore 971
IT - Italia 641
BR - Brasile 574
CN - Cina 549
VN - Vietnam 468
HK - Hong Kong 200
BD - Bangladesh 161
FR - Francia 106
DE - Germania 95
CA - Canada 71
AR - Argentina 64
KR - Corea 64
FI - Finlandia 58
GB - Regno Unito 57
MX - Messico 52
IN - India 45
IQ - Iraq 42
EC - Ecuador 36
NL - Olanda 33
RU - Federazione Russa 33
ZA - Sudafrica 33
ID - Indonesia 31
PK - Pakistan 31
UA - Ucraina 31
CO - Colombia 27
AT - Austria 24
TR - Turchia 21
UZ - Uzbekistan 20
ES - Italia 17
PH - Filippine 17
JM - Giamaica 16
NI - Nicaragua 16
VE - Venezuela 16
CL - Cile 15
PL - Polonia 15
JP - Giappone 14
DZ - Algeria 13
MA - Marocco 13
PY - Paraguay 13
SA - Arabia Saudita 13
GT - Guatemala 12
KE - Kenya 12
MY - Malesia 11
UY - Uruguay 11
HN - Honduras 10
IL - Israele 10
TN - Tunisia 10
ET - Etiopia 9
JO - Giordania 9
NP - Nepal 9
PE - Perù 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
EG - Egitto 8
PA - Panama 8
BO - Bolivia 7
KG - Kirghizistan 7
LB - Libano 7
TT - Trinidad e Tobago 7
RO - Romania 6
SV - El Salvador 6
AL - Albania 5
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
CW - ???statistics.table.value.countryCode.CW??? 5
CZ - Repubblica Ceca 5
OM - Oman 5
PS - Palestinian Territory 5
SE - Svezia 5
AU - Australia 4
DO - Repubblica Dominicana 4
LT - Lituania 4
PR - Porto Rico 4
SC - Seychelles 4
SN - Senegal 4
AM - Armenia 3
BY - Bielorussia 3
CH - Svizzera 3
EE - Estonia 3
KH - Cambogia 3
KZ - Kazakistan 3
NG - Nigeria 3
QA - Qatar 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
BB - Barbados 2
BE - Belgio 2
BN - Brunei Darussalam 2
DK - Danimarca 2
GY - Guiana 2
IE - Irlanda 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MK - Macedonia 2
NO - Norvegia 2
SY - Repubblica araba siriana 2
Totale 7.776
Salva come PNG Salva come JPEG
Città #
Singapore 427
Council Bluffs 408
San Jose 378
Ashburn 350
Dallas 238
Hong Kong 196
Ho Chi Minh City 162
Florence 139
Boardman 135
Beijing 109
Hefei 103
Hanoi 100
Milan 96
New York 63
Seoul 63
Lauterbourg 62
Santa Clara 61
São Paulo 60
The Dalles 49
Chicago 47
Los Angeles 47
Shanghai 47
Helsinki 41
Munich 41
Rome 36
Phoenix 34
Longmont 31
Atlanta 30
Da Nang 24
Rio de Janeiro 24
Haiphong 22
Montreal 22
Sesto Fiorentino 22
North Bergen 21
Naples 20
Noto 20
Guangzhou 18
Quito 18
Baghdad 17
Miano 17
Tashkent 17
Brasília 16
Brooklyn 16
Managua 16
Mexico City 14
Turin 14
Washington 14
Bari 13
Guayaquil 13
Vienna 13
Catania 12
Amsterdam 11
Buffalo 11
Dhaka 11
Hillsboro 11
Johannesburg 11
Lahore 11
Nairobi 11
Orem 11
Tokyo 11
Toronto 11
Frankfurt am Main 10
Guatemala City 10
Addis Ababa 9
Amman 9
Denver 9
Irvine 9
Kingston 9
Ninh Bình 9
Thái Nguyên 9
Turku 9
Warsaw 9
Wuhan 9
Belo Horizonte 8
Biên Hòa 8
Charlotte 8
Chennai 8
Karachi 8
Kyiv 8
Lappeenranta 8
London 8
Medellín 8
Miami 8
Montevideo 8
Myrtle Beach 8
Omaha 8
Portland 8
San Antonio 8
San Francisco 8
Campinas 7
Can Tho 7
Caracas 7
Erbil 7
Fortaleza 7
Hangzhou 7
Naaldwijk 7
Nuremberg 7
Ogden 7
Ribeirão Preto 7
Bishkek 6
Totale 4.380
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 198
Vaccination in Multiple Myeloma: Challenges and Strategies 155
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 152
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 143
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 142
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 139
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 138
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 134
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 134
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 132
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 129
The role of corticosteroids in the current treatment paradigm for myelofibrosis 129
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 125
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 125
Momelotinib in myelofibrosis 125
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 124
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 124
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 122
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 121
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 120
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 120
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 116
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 115
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 115
Iron chelation therapy 110
Belantamab mafodotin in multiple myeloma 108
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 107
Teclistamab-cqyv in multiple myeloma 105
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 102
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 102
Acalabrutinib in chronic lymphocytic leukemia 102
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 101
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 101
Myelodysplastic syndromes with ring sideroblasts 100
Selinexor in multiple myeloma 100
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 100
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 98
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 97
Cerebral pheohyphomycosis due to curvularia species 96
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 94
Elotuzumab in multiple myeloma 93
Avatrombopag for the Treatment of Immune Thrombocytopenia 92
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 92
Ivosidenib in acute myeloid leukemia 91
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 90
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 89
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 89
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 86
Glasdegib for the treatment of acute myeloid leukemia 85
Zanubrutinib for the treatment of chronic lymphocytic leukemia 80
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 79
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 78
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 78
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 76
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 75
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 75
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 74
Mosunetuzumab for the treatment of follicular lymphoma 70
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 67
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 64
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 64
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 64
Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives 60
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 60
Venetoclax in acute myeloid leukemia 58
Isatuximab in multiple myeloma 57
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 55
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions 54
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 47
Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches 47
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 46
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 45
Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? 42
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 41
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 39
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 36
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 36
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 35
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 34
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 33
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 32
Reshaping multiple myeloma treatment: recent breakthroughs 31
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 29
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 27
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 26
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 26
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 24
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 24
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 23
Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment 23
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 20
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 19
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 18
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 18
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 18
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 18
Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation 17
From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma 15
Mitochondrial Fitness as a Functional Immune Checkpoint in Cancer: Metabolic Plasticity, Tumor Evolution, and Immunotherapy 15
Rethinking On‐Target Off‐Tumor Toxicity as a Hematopoietic Continuum 14
Totale 7.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226 0 0 0 0 2 0 0 1 0 0 1 2
2022/202375 2 0 0 2 1 1 32 2 4 5 20 6
2023/2024530 10 17 105 84 49 64 24 17 17 8 19 116
2024/20251.200 45 99 33 62 59 45 24 61 178 124 123 347
2025/20264.481 424 237 407 302 701 317 484 223 366 432 271 317
2026/20271.631 343 117 421 750 0 0 0 0 0 0 0 0
Totale 7.933